Editorial Staff

Survey Finds Prescription Drug Prices Easy To Access, But Not Always Accurate

/in , , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Wide variation found in price of generics, less for brand-name drugs; consumers must navigate difficult terrain to find lowest price

BOSTON – It’s far easier to get prescription drug price information than to get similar numbers from hospitals or specialty physicians, but the information is not always reliable, according to a new survey published by Pioneer Institute.

Download

Researchers called 44 independent and chain drugstores across Massachusetts and asked for a 30-day supply in a common dosage of five generic and three brand-name drugs.  Callers said they were self-pay and pressed the stores for information about discounts. Massachusetts’ 2012 state law mandating price transparency does not cover retail pharmaceutical sales.

“There were virtually no transfers or dropped calls, no lengthy hold or wait times, and most of our callers were treated with courtesy,” said Barbara Anthony, primary author of “Transparency in Retail Drug Prices: Easy to Obtain but Accuracy May Be Doubtful.”  “However some workers weren’t well informed about the pharmacy’s discount programs and those working in chain stores didn’t refer the callers to drug discount program information on their websites.”

Although most Massachusetts residents have health insurance, between 3 and 4 percent are uninsured at any given time.  Combine that with the rise of high-deductible insurance plans and those who are underinsured, and the result is that many consumers are paying out-of-pocket for all or part of their prescription drugs.

There was significant variation among drugstores in the price of generic drugs, which account for 87 percent of prescriptions filled in the U.S. and typically cost one-third to one-tenth the price of brand-name drugs.

Atorvastatin, a popular generic used to control cholesterol, cost $4 at a pharmacy in Lunenburg and just under $199 at one in Boston.

See full chart in report.

See full chart in report.

There was a much narrower range for the three brand-name drugs about which researchers inquired.

Manufacturers’ coupons and those from companies like GoodRx and OneRx were found to reduce prices significantly for some generic drugs like Atorvastatin and Montelukast, a substitute for the antihistamine Singulair.  But the coupon price was sometimes higher than the price using store discounts for other drugs.

“Finding the lowest price, even among generic drugs, is tough terrain for consumers to navigate,” Anthony said. “Consumers need to consult coupon websites, call stores, shop, compare and try to find the best price at a time they are already in a vulnerable position,” she added.

The value of coupons was also mixed for brand-name drugs.  Using GoodRx reduced the price of Patanol, a popular eye-drop medication, from $335 to $268 at Walgreens, but provided little savings on other drugs.

It was often difficult to get accurate price information over the phone.  Sometimes drugstores couldn’t verify the price of a drug using a discount coupon until the transaction was run through the store’s computer system.  Some major chains will only disclose a “phantom” or average wholesale price for a drug because their computer systems are not able to provide the true price unless the prescription is actually processed.

“Consumers can’t be expected to physically go from pharmacy to pharmacy to get an accurate price,” said Pioneer’s Executive Director Jim Stergios.

The authors make several recommendations:

  • Pharmacy workers should receive better training about communicating prescription drug discount programs and they should refer customers to store websites, where applicable, for more information.
  • Retail drug stores should do more to inform consumers that they accept discount coupons.
  • Store computer systems need to be more consumer friendly and generate accurate prices to consumers who are shopping by phone; the inability to give an accurate price without filling the script impedes transparency and hurts consumers.
  • Consumers should not automatically assume that chain store prices are lower than independent drug store prices, and should know that many independent stores are willing to negotiate to match price. Shopping around can save money even on generic drugs.
  • Consumers should search the internet for discount drug coupons but they should not automatically assume that all coupon prices represent the best possible deal.
  • Prescription drug payers should adopt the level of transparency used by the Medicare program. There, beneficiaries receive an easy-to-read monthly report showing the amount Medicare paid to the pharmacy for each drug, the amount paid by the beneficiary and pharmacy payments from any other payers.

About the Authors     

Barbara Anthony, a lawyer, is a senior fellow in healthcare at Pioneer Institute focusing on healthcare price and quality transparency.  She is also an associate at the Harvard Kennedy School’s Center for Business and Government.  She served as Massachusetts Undersecretary for Consumer Affairs and Business Regulation from 2009 to 2015.

Scott Haller graduated from Northeastern University with a Bachelor’s Degree in Political Science. He started working at Pioneer Institute through the Northeastern’s Co-op Program and continues now as the Lovett C. Peters Fellow in Healthcare. He previously worked at the Office of the Inspector General.

About Pioneer

Pioneer Institute is an independent, non-partisan, privately funded research organization that seeks to improve the quality of life in Massachusetts through civic discourse and intellectually rigorous, data-driven public policy solutions based on free market principles, individual liberty and responsibility, and the ideal of effective, limited and accountable government.

Get Updates On Our Healthcare Cost Transparency Initiative!

Related Research

Study: Growth of Antibiotic-Resistant Infections Could Have Massive Human, Financial Costs

The world was blindsided by COVID-19, but a new Pioneer Institute study finds that even as we continue to wrestle with the pandemic, another threat looms that scientists have long known about but the nation has thus far failed to address: the growth of antibiotic-resistant infections. “Market dysfunction and perverse Medicare reimbursement rates have led to a growth in infections that resist antibiotics,” said Gunnar Esiason, author of “Antimicrobial Resistance: Learning from the current global health crisis to prevent another one.”  If we don’t solve this problem, the human and economic costs are likely to be astronomical.”

Study: Growing Drug Rebates Hurt Both Consumers and Healthcare System

Ever-larger rebates are distorting the market for branded drugs and producing outcomes that often benefit neither consumers nor the healthcare system, according to a new study published by Pioneer Institute.

Study: Shift from Highest-Priced Healthcare Providers Would Generate Tremendous Savings

Consumers in just one Massachusetts county could have saved nearly $22 million in a single year and $116.6 million adjusted for inflation over four years if they switched from using the most expensive providers for 16 shoppable healthcare services to those whose prices were closer to average, according to a new study published by Pioneer Institute.

Pioneer Urges Future COVID-19 Study and Recommendations Task Force to Consider Impact on Nursing Home Residents

After over 5,000 people have died of COVID-19 in Massachusetts nursing homes, Pioneer Institute is issuing an open letter to the state’s future COVID-19 health equity task force that outlines an extensive list of recommendations on infection control and preparedness in eldercare facilities.

Open Letter: COVID-19 Study and Recommendations Task Force Established Pursuant to Massachusetts Bill H.4672

Pioneer hopes the members of this important task force will be appointed as soon as possible and that they will look into recommendations to address Covid-19 among the aged and in the state’s nursing homes. Read our Open Letter.

Combatting COVID-19: Life in the MGH Emergency Room

0 Comments
/
Join host Joe Selvaggi and Pioneer Senior Fellow Josh Archambault as they talk with Dr. David King about the experience of being in emergent care during a pandemic and lockdown. They explore the challenges of coping with a poorly understood virus during a lockdown, all while continuing to serve the sick.

Study Finds Pandemic Likely to Negatively Impact Biopharmaceutical Sector

Contrary to conventional wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical companies, a new Pioneer Institute study finds many companies will emerge from the pandemic commercially weaker, dealing with delays in new product launches and with fewer resources to invest in research and development.

National Study Finds Most States Lack Healthcare Price Transparency Laws

At a time when the coronavirus pandemic has caused massive shifts in state policies on telehealth and scope of practice in healthcare, a new Pioneer Institute study underscores that most of the 50 states continue to suffer from weak laws regarding price transparency.  The study identified states that have laws that require carriers, providers or both to provide personalized cost information to consumers before obtaining healthcare services.  Fully 33 states placed in the lowest of the three broad analytic tiers on the strength of their state healthcare transparency laws. 

A Tipping Point for Telehealth – Bringing Healthcare into Your Home

0 Comments
/
This week on "Hubwonk," Joe Selvaggi and Josh Archambault talk with Dr. Roy Schoenberg, Chief Executive of Amwell, a global telehealth technology company headquartered in Boston, about the promise of telemedicine and how the COVID-19 pandemic has catalyzed broader adoption.

New Study Calls for Re-thinking Massachusetts’ COVID-19 Care Standards

Pioneer's new study raises concerns about the Massachusetts Department of Public Health’s (DPH’s) Crises Standards of Care (CSC) issued earlier this month, which bear the earmarks of a state bureaucratic effort and should be rethought under a process that includes a thorough vetting by Massachusetts citizens.

New Report: Quality Adjusted Life Years (QALY) Methodology Discriminates Against Older Americans, Threatens to Deny Seniors Access to Life-Saving Care

New report asserts that with older americans more vulnerable during the COVID-19 pandemic, all health plans should avoid using the QALY methodology when assessing the value of care for older patients

Baker needs to expand telehealth further

0 Comments
/
This op-ed appeared in Commonwealth magazine on March 25th, 2020. Coronavirus…
A Woman Helping a Disabled Man in a Wheelchair

New Report & Legal Analysis Suggests ICER’s Quality Adjusted Life Years Methodology Violates the Americans with Disabilities Act

A new report, "The Legality of QALY under the ADA," outlines several potential legal violations and negative implications for disabled individuals related to the adoption of the QALY approach to drug value assessment, used most prominently by ICER.

Pioneer Poll: MA Healthcare Consumers Overwhelmingly Want Price Information on Services, but Few Know How to Get It

A new Pioneer poll shows seven out of ten Massachusetts workers who get their health insurance through their employers want to know the price of a healthcare procedure before they obtain it, but most of them do not how to obtain such information, even though information is already available through their insurers’ cost estimator tools.

Pioneer Institute to Present Results of New Consumer Poll Monday at State House Healthcare Price Transparency Event

BOSTON – Pioneer Institute will present the results of a new…

Public statement on new federal rule eliminating “skimming” of dues from caregivers’ Medicaid payments

Pioneer Institute applauds a new rule announced by the U.S. Centers…

Making Healthcare Prices Accessible

Today, Pioneer Institute filed a Public Comment with the federal…